These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 16760751

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Chronic inflammatory bowel diseases. Update on evidence-based therapy].
    MMW Fortschr Med; 2005 Apr 28; 147(17):58-9. PubMed ID: 15903063
    [No Abstract] [Full Text] [Related]

  • 3. The ocular manifestations of inflammatory bowel disease.
    Taylor SR, McCluskey P, Lightman S.
    Curr Opin Ophthalmol; 2006 Dec 28; 17(6):538-44. PubMed ID: 17065922
    [Abstract] [Full Text] [Related]

  • 4. Just a spoonful of sugar helps the medicine go down... If only it was that simple! nonadherence in inflammatory bowel disease.
    Kane S.
    Am J Gastroenterol; 2007 Jul 28; 102(7):1427-8. PubMed ID: 17593159
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Review article: steroid resistance in inflammatory bowel disease - mechanisms and therapeutic strategies.
    Creed TJ, Probert CS.
    Aliment Pharmacol Ther; 2007 Jan 15; 25(2):111-22. PubMed ID: 17229236
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'?
    Giannini EG, Kane SV, Testa R, Savarino V.
    Dig Liver Dis; 2005 Oct 15; 37(10):723-31. PubMed ID: 16023905
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Review article: inflammatory bowel disease--empowering the patient and improving outcome.
    Robinson A.
    Aliment Pharmacol Ther; 2004 Oct 15; 20 Suppl 4():84-7. PubMed ID: 15352900
    [Abstract] [Full Text] [Related]

  • 13. Immunosuppression in inflammatory bowel disease: traditional, biological or both?
    Van Assche G, Vermeire S, Rutgeerts P.
    Curr Opin Gastroenterol; 2009 Jul 15; 25(4):323-8. PubMed ID: 19417645
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Are we ready for top-down therapy for inflammatory bowel diseases: pro.
    van der Woude CJ, Hommes DW.
    Expert Rev Gastroenterol Hepatol; 2007 Dec 15; 1(2):243-8. PubMed ID: 19072416
    [Abstract] [Full Text] [Related]

  • 16. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications.
    Atreya I, Neurath MF.
    Expert Rev Gastroenterol Hepatol; 2008 Feb 15; 2(1):23-34. PubMed ID: 19072367
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Risks of combining immunosuppressive and biological treatments in inflammatory bowel disease.
    Roblin X, Phelip JM.
    Arch Intern Med; 2008 Mar 24; 168(6):667; author reply 667-8. PubMed ID: 18362263
    [No Abstract] [Full Text] [Related]

  • 20. Predictors of medication adherence in inflammatory bowel disease.
    Ediger JP, Walker JR, Graff L, Lix L, Clara I, Rawsthorne P, Rogala L, Miller N, McPhail C, Deering K, Bernstein CN.
    Am J Gastroenterol; 2007 Jul 24; 102(7):1417-26. PubMed ID: 17437505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.